10MO: Preventing moderate to severe dermatologic adverse events in first-line EGFR-mutant advanced NSCLC treated with amivantamab plus lazertinib: Early success of the COCOON trial

作者：N. Girard, Wei Li, A.I. Spira, Jerome A. Feldman, Mei Ting Mak, Maxwell Sauder, F. Bozorgmehr, P-J. Voon, Cheng‐Ta Yang, J. Cundom, Jorgé Nieva, P. Tomasini, I. Cicin, T. Romero, S. Sheng, J. Bauml, Jorge Simões, P. Mahadevia, Mark Wildgust, B.C. Cho · 发表于：Journal of Thoracic Oncology · 年份：2025 · DOI：10.1016/s1556-0864(25)00205-9 · 被引用次数：15 · 研究领域：Colorectal Cancer Treatments and Studies、Lung Cancer Treatments and Mutations、Lymphoma Diagnosis and Treatment